Antonio Passaro, Medical Oncologist and a Medical Director with High Specialization Assignment at the European Institute of Oncology, shared a post on LinkedIn:
“Honored to be part of this publication in the New England Journal of Medicine, a milestone in lung cancer research and drug development for patients with EGFR-mutated disease.
This work represents not only scientific progress, but also a concrete step toward reshaping the actual therapeutic landscape and improving outcomes for our patients, using an innovative combination.
Proud to contribute, together with outstanding colleagues worldwide, to advancing the frontier of thoracic oncology.”
Title: Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Authors: James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I. Spira, Nicolas Girard, Yu Jung Kim, Se-Hoon Lee, Yurii Ostapenko, Pongwut Danchaivijitr, Baogang Liu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Benjamin Besse, Antonio Passaro, Ki-Hyeong Lee, Hailin Xiong, Soon-Hin How, Ying Cheng, Gee-Chen Chang, Hiroshige Yoshioka, Michael Thomas, Danny Nguyen, Sai-Hong Ignatius Ou, Sanjay Mukhedkar, Kumar Prabhash, Manolo D’Arcangelo, Jorge Alatorre-Alexander, Juan Carlos Vázquez Limón, Sara Alves, Daniil Stroyakovskiy, Marina Peregudova, Mehmet Ali Nahit Şendur, Ozan Yazici, Raffaele Califano, Vanesa Gutiérrez Calderón, Filippo de Marinis, Sang-We Kim, Shirish M. Gadgeel, Scott Owen, John Xie, Tao Sun, Jaydeep Mehta, Raja Venkatasubramanian, Mariah Ennis, Elizabeth Fennema, Mahesh Daksh, Amy Roshak, Julie Man, Roland E. Knoblauch, Joshua M. Bauml, Mahadi Baig, Sujay Shah, Seema Sethi, Byoung Chul Cho
Read The Full Article at NEJM.
More posts featuring Antonio Passaro on OncoDaily.